Xiaojuan Xiao

Hunan Province Key Laboratory Of Basic And Applied Hematology
Changsha, 410013, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Calpain-2 inhibition alleviates hypercalcemia-driven multiple myeloma progression.

Calpain-2 inhibition alleviates hypercalcemia-driven multiple myeloma progression.

Journal: Biochemical pharmacology
Published: March 13, 2026

HLTF cooperates with GATA1 to activate transcriptional programs and chromatin remodeling during erythroid development.

HLTF cooperates with GATA1 to activate transcriptional programs and chromatin remodeling during erythroid development.

Journal: Nucleic acids research
Published: August 06, 2025

The function and mechanism of clinical trial agent CPI-613 in multiple myeloma.

The function and mechanism of clinical trial agent CPI-613 in multiple myeloma.

Journal: Biochemical pharmacology
Published: July 20, 2024

Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression.

Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression.

Journal: Oncogene
Published: July 18, 2024

Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets.

Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets.

Journal: Cell death & disease
Published: April 15, 2024

Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic target.

Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic target.

Journal: Carcinogenesis
Published: March 07, 2024

Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma.

Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma.

Journal: Cancers
Published: January 15, 2023

The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies.

The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies.

Journal: Cancers
Published: January 06, 2023

Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo.

Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo.

Journal: Biomaterials
Published: December 30, 2022

HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia.

HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 12, 2022

Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.

Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.

Journal: Cancer letters
Published: May 11, 2022

A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia.

A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia.

Journal: BioMed research international
Published: March 31, 2022
Showing 1-12 of 41

Last Updated: 09/26/2026